Search PubMed⌕ Search

PubMed · 16094929

Overactive bladder.

Abstract

Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local pathological or hormonal factors. It is a common complaint of men and women alike, with estimates of 22 million sufferers. ApproximateLy 70% of men with bladder outflow obstruction will have some symptoms of OAB. The exact pathophysiology of OAB in bladder outflow obstruction is yet to be elucidated; evidence to date points to changes in both the efferent and afferent innervation and the detrusor. Management of OAB can be is generally with pharmacological agents such as anticholinergics or operative measures such as the 'Clam' cystoplasty. More recent treatment modalities include intravesicaL oxybutynin, intradetrusor botulinum toxin and neuromodulation. More specific treatment options for OAB in bladder outflow obstruction include relief of the obstruction with surgical (e.g. transurethraL resection of prostate) or pharmaceutical (e.g. a blockers) methods.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rajesh Kavia, Faiz Mumtaz. 2005. Overactive bladder.. https://doi.org/10.1177/146642400512500411

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Review article: the management of achalasia - a comparison of different treatment modalities.

BACKGROUND: Achalasia is an uncommon primary oesophageal motor disorder with an unknown aetiology. Therapeutic options for achalasia are aimed at decreasing the lower oesophageal sphincter pressure, improving the oesophageal empting, and most importantly, relieving the symptoms of achalasia. Modalities for treatment include pharmacologic, endoscopic, pneumatic dilatation and surgical. The decision of which modality to use involves the consideration of multiple clinical and economic factors. AIM: To review the management strategies currently available for achalasia. METHODS: A Medline search identified the original articles and reviews the published in the English language literature between 1966 and 2006. RESULTS: The results reveal that pharmacotherapy, injection of botulinum toxin, pneumatic dilatation and minimally invasive surgical oesophagomyotomy are variably effective at controlling the symptoms of achalasia but that each modality has specific strengths and weaknesses which make them each suitable in certain populations. Overall, pharmacologic therapy results in the shortest lived, least durable response followed by botulinum toxin injection, pneumatic dilatation and surgery, respectively. CONCLUSION: The optimal treatment for achalasia remains an area of controversy given our lack of complete understanding about the pathophysiology of the disease as well as the high numbers of clinical relapse after treatment. Further research focusing on optimal dosing of botulinum toxin injection and optimal timing of repeated graduated pneumatic dilatations could add to our knowledge regarding long-term therapy.

Anti-Dyskinesia Agents↗